Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Induces Death Receptor 5 Networks That Are Highly Organized

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

Targeting Trail Towards the Clinic

(2011) Devalingam Mahalingam et al.   CURRENT DRUG TARGETS

Signaling clusters in the cell membrane

(2011) Niña C Hartman et al.   CURRENT OPINION IN CELL BIOLOGY

Oligomeric Interactions of Sarcolipin and the Ca-ATPase

(2011) Joseph M. Autry et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

T-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters

(2011) B. N. Manz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity

(2010) V. Pavet et al.   CANCER RESEARCH

LBY135, a novel anti-DR5 agonistic antibody induces tumor cell-specific cytotoxic activity in human colon tumor cell lines and xenografts

(2010) Jing Li et al.   DRUG DEVELOPMENT RESEARCH

Specificity for Homooligomer versus Heterooligomer Formation in Integrin Transmembrane Helices

(2010) Hua Zhu et al.   JOURNAL OF MOLECULAR BIOLOGY

Relative Affinity of Calcium Pump Isoforms for Phospholamban Quantified by Fluorescence Resonance Energy Transfer

(2010) Zhanjia Hou et al.   JOURNAL OF MOLECULAR BIOLOGY

Ligand-independent signaling by disulfide-crosslinked dimers of the p75 neurotrophin receptor

(2009) M. Vilar et al.   JOURNAL OF CELL SCIENCE

Nanoscale Arrangement of Apoptotic Ligands Reveals a Demand for a Minimal Lateral Distance for Efficient Death Receptor Activation

(2009) Julia Ranzinger et al.   NANO LETTERS

Activation of the p75 Neurotrophin Receptor through Conformational Rearrangement of Disulphide-Linked Receptor Dimers

(2009) Marçal Vilar et al.   NEURON

TRAIL receptor signalling and modulation: Are we on the right TRAIL?

(2008) Devalingam Mahalingam et al.   CANCER TREATMENT REVIEWS

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

(2008) C Adams et al.   CELL DEATH AND DIFFERENTIATION

Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors

(2008) D Ross Camidge   EXPERT OPINION ON BIOLOGICAL THERAPY

Oxidative Stress Promotes Ligand-independent and Enhanced Ligand-dependent Tumor Necrosis Factor Receptor Signaling

(2008) Hatice Z. Ozsoy et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phosphomimetic Mutations Increase Phospholamban Oligomerization and Alter the Structure of Its Regulatory Complex

(2008) Zhanjia Hou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody

(2008) A. Shanker et al.   JNCI-Journal of the National Cancer Institute

Anti-Gout Agent Allopurinol Exerts Cytotoxicity to Human Hormone-Refractory Prostate Cancer Cells in Combination with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

(2008) T. Yasuda et al.   MOLECULAR CANCER RESEARCH